Davut Cekmecelioglu1,2, Ourania Preventza1,2, Kathryn G Dougherty2, Subhasis Chatterjee1,2,3, Susan Y Green1,4, Guilherme V Silva5, Jose G Díez5,6, Joseph S Coselli1,2. 1. Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA. 2. Section of Adult Cardiac Surgery, Department of Cardiovascular Surgery, Texas Heart Institute and CHI St Luke's Health-Baylor St Luke's Medical Center, Houston, Texas, USA. 3. Division of General Surgery, Michael E. DeBakey Department of Surgery, Baylor College Medicine, Houston, Texas, USA. 4. Office of Surgical Research, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA. 5. Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. 6. Department of Cardiology, Texas Heart Institute, Houston Texas, USA.
Abstract
BACKGROUND: Open surgical repair of a failed valve-sparing aortic root replacement (VSARR) or stentless bioroot aortic root replacement (bio-ARR) entails significant operative risks. Whether valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is feasible in patients with a previous VSARR or stentless bio-ARR remains unclear, given lingering concerns about the ill-defined aortic annulus in these patients and the potential for coronary obstruction. We present our experience with patients who had a previous VSARR or stentless bio-ARR and underwent ViV-TAVR to repair a degenerated aortic valve with combined valvular disease, aortic insufficiency and aortic stenosis. METHODS: In this retrospective data review, we identified and analyzed consecutive patients with a previous VSARR or stentless bio-ARR who underwent ViV-TAVR between December 1, 2014 and August 31, 2019. RESULTS: ViV-TAVR was performed in twelve high-risk patients with previous VSARR or bio-ARR during the study period. Of these, seven received Medtronic Freestyle porcine stentless bioprosthetic aortic roots, three received homograft aortic roots, one underwent a Ross procedure and one underwent VSARR. ViV-TAVR restored satisfactory valve function in all patients, and technical success was 100%. No patient had more than mild regurgitation after implantation. No thirty-day mortality was seen. One patient had major bleeding after transapical access, one patient had a transient ischemic stroke, and one patient needed permanent pacemaker implantation. At a median last follow-up of 21.5 months (interquartile range, 9.0-69.0 months), all patients remained alive and had satisfactory valve function. CONCLUSIONS: In this study, ViV-TAVR was a clinically effective option for treating patients with a failed stentless bio-ARR or previous VSARR. Short-term and intermediate-term results after these procedures were favorable. These findings may have important implications for treating high-risk patients with structural aortic root deterioration and call for better transcatheter heart valves that are suitable for treating aortic insufficiency. 2021 Annals of Cardiothoracic Surgery. All rights reserved.
BACKGROUND: Open surgical repair of a failed valve-sparing aortic root replacement (VSARR) or stentless bioroot aortic root replacement (bio-ARR) entails significant operative risks. Whether valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is feasible in patients with a previous VSARR or stentless bio-ARR remains unclear, given lingering concerns about the ill-defined aortic annulus in these patients and the potential for coronary obstruction. We present our experience with patients who had a previous VSARR or stentless bio-ARR and underwent ViV-TAVR to repair a degenerated aortic valve with combined valvular disease, aortic insufficiency and aortic stenosis. METHODS: In this retrospective data review, we identified and analyzed consecutive patients with a previous VSARR or stentless bio-ARR who underwent ViV-TAVR between December 1, 2014 and August 31, 2019. RESULTS: ViV-TAVR was performed in twelve high-risk patients with previous VSARR or bio-ARR during the study period. Of these, seven received Medtronic Freestyle porcine stentless bioprosthetic aortic roots, three received homograft aortic roots, one underwent a Ross procedure and one underwent VSARR. ViV-TAVR restored satisfactory valve function in all patients, and technical success was 100%. No patient had more than mild regurgitation after implantation. No thirty-day mortality was seen. One patient had major bleeding after transapical access, one patient had a transient ischemic stroke, and one patient needed permanent pacemaker implantation. At a median last follow-up of 21.5 months (interquartile range, 9.0-69.0 months), all patients remained alive and had satisfactory valve function. CONCLUSIONS: In this study, ViV-TAVR was a clinically effective option for treating patients with a failed stentless bio-ARR or previous VSARR. Short-term and intermediate-term results after these procedures were favorable. These findings may have important implications for treating high-risk patients with structural aortic root deterioration and call for better transcatheter heart valves that are suitable for treating aortic insufficiency. 2021 Annals of Cardiothoracic Surgery. All rights reserved.
Authors: Michael A Borger; Kriengchai Prasongsukarn; Susan Armstrong; Christopher M Feindel; Tirone E David Journal: Ann Thorac Surg Date: 2007-09 Impact factor: 4.330
Authors: Danny Dvir; John Webb; Stephen Brecker; Sabine Bleiziffer; David Hildick-Smith; Antonio Colombo; Fleur Descoutures; Christian Hengstenberg; Neil E Moat; Raffi Bekeredjian; Massimo Napodano; Luca Testa; Thierry Lefevre; Victor Guetta; Henrik Nissen; José-María Hernández; David Roy; Rui C Teles; Amit Segev; Nicolas Dumonteil; Claudia Fiorina; Michael Gotzmann; Didier Tchetche; Mohamed Abdel-Wahab; Federico De Marco; Andreas Baumbach; Jean-Claude Laborde; Ran Kornowski Journal: Circulation Date: 2012-10-10 Impact factor: 29.690
Authors: John G Webb; Dale J Murdoch; Maria C Alu; Anson Cheung; Aaron Crowley; Danny Dvir; Howard C Herrmann; Susheel K Kodali; Jonathon Leipsic; D Craig Miller; Philippe Pibarot; Rakesh M Suri; David Wood; Martin B Leon; Michael J Mack Journal: J Am Coll Cardiol Date: 2019-06-04 Impact factor: 24.094
Authors: John G Webb; Michael J Mack; Jonathon M White; Danny Dvir; Philipp Blanke; Howard C Herrmann; Jonathon Leipsic; Susheel K Kodali; Raj Makkar; D Craig Miller; Philippe Pibarot; Augusto Pichard; Lowell F Satler; Lars Svensson; Maria C Alu; Rakesh M Suri; Martin B Leon Journal: J Am Coll Cardiol Date: 2017-05-09 Impact factor: 24.094